|
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
SINGAPORE, Nov 01, 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
3F Mosquito, a fragrance made up of specialized oils sourced from botanicals that mosquitoes avoid, has shown 100% repellency against mosquitoes in laboratory testing. Global BioLife contracted U.S-based Snell Scientifics LLC ("Snell") in Meansville, Georgia to conduct the mosquito studies for the mosquito deterring technologies.
In August 2017 SeD announced that Global BioLife was collaborating with U.S-based Chemia Corporation to develop a suite of fragrances for medical applications referred to as 3F (Functional Fragrance Formulation). Global BioLife entered into further collaboration with Chemia to co-develop 3F Mosquito for laundry detergents, shampoos and lotions.
3F Mosquito products are based on extensive research of botanical oils which possess mosquito repelling properties. When 3F is infused into products such as detergents, shampoos, and lotions, consumers will be provided with multiple layers of protection against mosquito bites, a revolutionary alternative to traditional mosquito repellents.
"Chemia is very excited to introduce these sustainable and tested fragrances to provide natural alternatives to protecting consumers from the risk of mosquito transmitted diseases," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
The uniquely-designed mosquito deterring paints and functional fabric both deter mosquitoes by chemical-free photonic means; a wavelength of light is emitted that mosquitoes avoid. Snell reported that Global BioLife's photonic mosquito paints and mosquito fabric both exhibit degrees of repellency effective against mosquitoes.
Global BioLife and Chemia have designed the mosquito deterring fabric for use in outdoor apparel, hats, tents, and other camping gear. The mosquito deterring paints were designed as exterior paints for homes as well as commercial applications. These new mosquito deterring technologies are non-chemical methods of repelling mosquitoes for consumers. Mr. Daryl Thompson, Global BioLife Director of Scientific Initiatives, said "The objective in the design of 3F Mosquito was to identify and create a suitable formula that was both pleasant and would excel in protective abilities against mosquitoes. These oils are scientifically proven to affect mosquitoes' receptors, essentially making the mosquito blind to your presence. 3F offers a pleasant scent while providing layers of protection to keep people safe from mosquito bites."
The market for safe mosquito repellents and deterrents is growing as the risk of Zika grows. The most vulnerable group of our population at highest risk for Zika infection may be pregnant women, because of their avoidance and dislike of products containing Deet. The US Center for Disease Control has released multiple statements that the use of Deet is safe, however pregnant women continue to be hesitant to use Deet-containing products.
Dr. Peggy Tang, Global BioLife's CEO, commented: "We expect that these new techniques for fighting mosquito bites will be very appealing to consumers. We are providing unique and useful products, free of harsh chemicals. Due to the perceived toxicity of Deet and the avoidance of chemicals by consumers, Global BioLife's chemical-free products will have a direct advantage over traditional mosquito repellents."
"Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This collaboration marks one of the first steps in actively changing the game of healthcare," said SeD and Global BioLife Executive Chairman Mr. Chan Heng Fai.
Mr. Thomas Meyer added: "This groundbreaking partnership with Global BioLife sets the stage for a steady stream of innovative fragrances that feature functional properties in various consumer product applications."
In addition to 3F Mosquito, Global BioLife is working with Chemia on the formulation of additional 3F fragrances to fight stress and anxiety and 3F for anti-viral medical applications.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") and Australian Exchange-listed Holista CollTech Limited ("Holista") in equal proportions of 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com About Chemia Corporation
Chemia Fragrance and Flavor provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. For more information, please visit: http://www.chemiacorp.com.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026 Feb 13, 2026 22:50 JST
|  Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026 Feb 13, 2026 22:33 JST
|  Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts Feb 13, 2026 22:24 JST
|  MHI Successfully Demonstrates Production of Liquid Synthetic Fuels through an integrated Process Utilizing SOEC Co-Electrolysis and FT Synthesis Feb 13, 2026 22:03 JST
|  JCB Sponsors the NHK Symphony Orchestra Singapore Concert 2026 - Celebrating 60 Years of Singapore-Japan Relations Feb 13, 2026 14:00 JST
|  Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense Feb 12, 2026 19:59 JST
|  Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk Feb 12, 2026 16:09 JST
|  Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty Feb 12, 2026 12:13 JST
|  Premiere of Three-Row Highlander BEV in North America Feb 11, 2026 14:25 JST
|  Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season Feb 10, 2026 18:25 JST
|  Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business Feb 10, 2026 17:53 JST
|  KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System Feb 10, 2026 14:15 JST
|  Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China Feb 10, 2026 13:34 JST
|  NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition Feb 09, 2026 21:18 JST
|  CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence Feb 09, 2026 14:28 JST
|  JCB Announces Collaboration with Resorts World Sentosa in Singapore Feb 09, 2026 14:00 JST
|  Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026 Feb 09, 2026 11:00 JST
|  Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market Feb 06, 2026 13:34 JST
|  Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products Feb 06, 2026 11:50 JST
|  Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan Feb 06, 2026 11:31 JST
|
More Latest Release >>
|